Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Capital Expenditures (2020 - 2025)

LifeStance Health (LFST) has disclosed Capital Expenditures for 6 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 73.16% to $10.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.1 million, a 67.51% increase, with the full-year FY2025 number at $36.1 million, up 67.51% from a year prior.
  • Capital Expenditures was $10.9 million for Q4 2025 at LifeStance Health, up from $10.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $38.7 million in Q4 2021 to a low of $5.1 million in Q3 2024.
  • A 5-year average of $12.6 million and a median of $10.3 million in 2022 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 151.87% in 2022; the steepest drop was 73.15% in 2022.
  • LifeStance Health's Capital Expenditures stood at $38.7 million in 2021, then plummeted by 73.15% to $10.4 million in 2022, then grew by 9.92% to $11.4 million in 2023, then tumbled by 44.8% to $6.3 million in 2024, then surged by 73.16% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for LFST's Capital Expenditures are $10.9 million (Q4 2025), $10.3 million (Q3 2025), and $7.8 million (Q2 2025).